Literature DB >> 29924704

Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial.

Takamasa Kayama1, Shinya Sato1, Kaori Sakurada1, Junki Mizusawa1, Ryo Nishikawa1, Yoshitaka Narita1, Minako Sumi1, Yasuji Miyakita1, Toshihiro Kumabe1, Yukihiko Sonoda1, Yoshiki Arakawa1, Susumu Miyamoto1, Takaaki Beppu1, Kazuhiko Sugiyama1, Hirohiko Nakamura1, Motoo Nagane1, Yoko Nakasu1, Naoya Hashimoto1, Mizuhiko Terasaki1, Akira Matsumura1, Eiichi Ishikawa1, Toshihiko Wakabayashi1, Yasuo Iwadate1, Shiro Ohue1, Hiroyuki Kobayashi1, Manabu Kinoshita1, Kenichiro Asano1, Akitake Mukasa1, Katsuyuki Tanaka1, Akio Asai1, Hideo Nakamura1, Tatsuya Abe1, Yoshihiro Muragaki1, Koichi Iwasaki1, Tomokazu Aoki1, Takao Watanabe1, Hikaru Sasaki1, Shuichi Izumoto1, Masahiro Mizoguchi1, Takayuki Matsuo1, Hideo Takeshima1, Motohiro Hayashi1, Hidefumi Jokura1, Takashi Mizowaki1, Eiji Shimizu1, Hiroki Shirato1, Masao Tago1, Hiroshi Katayama1, Haruhiko Fukuda1, Soichiro Shibui1.   

Abstract

Purpose Whereas whole-brain radiotherapy (WBRT) has been the standard treatment of brain metastases (BMs), stereotactic radiosurgery (SRS) is increasingly preferred to avoid cognitive dysfunction; however, it has not been clearly determined whether treatment with SRS is as effective as that with WBRT or WBRT plus SRS. We thus assessed the noninferiority of salvage SRS to WBRT in patients with BMs. Patients and Methods Patients age 20 to 79 years old with performance status scores of 0 to 2-and 3 if caused only by neurologic deficits-and with four or fewer surgically resected BMs with only one lesion > 3 cm in diameter were eligible. Patients were randomly assigned to WBRT or salvage SRS arms within 21 days of surgery. The primary end point was overall survival. A one-sided α of .05 was used. Results Between January 2006 and May 2014, 137 and 134 patients were enrolled in the WBRT and salvage SRS arms, respectively. Median overall survival was 15.6 months in both arms (hazard ratio, 1.05; 90% CI, 0.83 to 1.33; one-sided P for noninferiority = .027). Median intracranial progression-free survival of patients in the WBRT arm (10.4 months) was longer than that of patients in the salvage SRS arm (4.0 months). The proportions of patients whose Mini-Mental Status Examination and performance status scores that did not worsen at 12 months were similar in both arms; however, 16.4% of patients in the WBRT arm experienced grade 2 to 4 cognitive dysfunction after 91 days postenrollment, whereas only 7.7% of those in the SRS arm did ( P = .048). Conclusion Salvage SRS is noninferior to WBRT and can be established as a standard therapy for patients with four or fewer BMs.

Entities:  

Year:  2018        PMID: 29924704     DOI: 10.1200/JCO.2018.78.6186

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  28 in total

1.  Population-based estimates of survival among elderly patients with brain metastases.

Authors:  Nayan Lamba; Rachel Brigell Kearney; Paul J Catalano; Michael J Hassett; Patrick Y Wen; Daphne A Haas-Kogan; Ayal A Aizer
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

Review 2.  Health related quality of life trajectories after stereotactic radiosurgery for brain metastases: a systematic review.

Authors:  Adomas Bunevicius; Laura Donovan; Jason Sheehan
Journal:  J Neurooncol       Date:  2022-07-04       Impact factor: 4.506

Review 3.  Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.

Authors:  Ayal A Aizer; Nayan Lamba; Manmeet S Ahluwalia; Kenneth Aldape; Adrienne Boire; Priscilla K Brastianos; Paul D Brown; D Ross Camidge; Veronica L Chiang; Michael A Davies; Leland S Hu; Raymond Y Huang; Timothy Kaufmann; Priya Kumthekar; Keng Lam; Eudocia Q Lee; Nancy U Lin; Minesh Mehta; Michael Parsons; David A Reardon; Jason Sheehan; Riccardo Soffietti; Hussein Tawbi; Michael Weller; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2022-10-03       Impact factor: 13.029

4.  Management of brain metastasis from eccrine porocarcinoma: illustrative case.

Authors:  Ryuichi Noda; Tomohiro Inoue; Sho Tsunoda; Masafumi Segawa; Yoshio Masuda; Teppei Morikawa; Atsuya Akabane
Journal:  J Neurosurg Case Lessons       Date:  2021-06-28

5.  Cerebellopontine angle metastasis of a neuroendocrine tumor mimicking vestibular schwannoma: A case report.

Authors:  Shuhei Yamada; Noriyuki Kijima; Manabu Kinoshita; Shinichiro Shinzaki; Kazuaki Sato; Kansuke Kido; Ryuichi Hirayama; Naoki Kagawa; Tetsuo Takehara; Eiichi Morii; Haruhiko Kishima
Journal:  Surg Neurol Int       Date:  2022-06-23

6.  Combination laser interstitial thermal therapy plus stereotactic radiotherapy increases time to progression for biopsy-proven recurrent brain metastases.

Authors:  Matthew M Grabowski; Ethan S Srinivasan; Eugene J Vaios; Eric W Sankey; Balint Otvos; Daria Krivosheya; Alex Scott; Michael Olufawo; Jun Ma; Elena I Fomchenko; James E Herndon; Albert H Kim; Veronica L Chiang; Clark C Chen; Eric C Leuthardt; Gene H Barnett; John P Kirkpatrick; Alireza M Mohammadi; Peter E Fecci
Journal:  Neurooncol Adv       Date:  2022-06-02

Review 7.  Brain metastasis: Recent treatment modalities and future-perspectives.

Authors:  Atsuto Katano; Hideomi Yamashita
Journal:  Oncol Lett       Date:  2022-04-29       Impact factor: 3.111

8.  Neuro-oncology: a selected review of ASCO 2016 abstracts.

Authors:  Marc C Chamberlain
Journal:  CNS Oncol       Date:  2016-09-12

9.  Association of Neurosurgical Resection With Development of Pachymeningeal Seeding in Patients With Brain Metastases.

Authors:  Daniel N Cagney; Nayan Lamba; Sumi Sinha; Paul J Catalano; Wenya Linda Bi; Brian M Alexander; Ayal A Aizer
Journal:  JAMA Oncol       Date:  2019-05-01       Impact factor: 31.777

10.  A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma.

Authors:  Nancy Ann Oberheim Bush; Jacob S Young; Yalan Zhang; Cecilia L Dalle Ore; Annette M Molinaro; Jennie Taylor; Jennifer Clarke; Michael Prados; Steve E Braunstein; David R Raleigh; Susan M Chang; Mitchel S Berger; Nicholas A Butowski
Journal:  J Neurooncol       Date:  2021-06-14       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.